

1103326-0678

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

JUN 21 2005

Applicant : A. Bayati
Serial No. : 10/053,279 Examiner: Michael Hartley
Filed : January 17, 2002 Group Art Unit: 1616
For : THERAPY FOR FUNCTIONAL DYSPEPSIA

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8	
I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below at the facsimile number <u>703-872-9306</u> .	
Richard J. Sterner Agent Name	35,372 PTO Reg. No.
<i>Richard J. Sterner</i> Signature	June 21, 2005 Date of Signature

Facsimile No.: 703-872-9306

No. of pages: 9

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR AMENDMENT OF INVENTORSHIP UNDER 37 C.F.R. §1.48(a)

Sir:

It has come to the attention of the Assignee and the undersigned that there is a second person who should be named as inventor of the subject matter claimed in the above-referenced application. Accordingly, it is hereby requested that the inventorship of the instant application be amended by addition of said inventor, Claes Ekman. Upon implementation of this


Amendment, the named inventors in this application will be Alfred Bayati and Claes Ekman.

The Commissioner is hereby authorized to charge the \$130 processing fee required under 37 C.F.R. §1.17(i), as well as any other fees that may be required for any reason, to Deposit Account No. 23-1703.

Accompanying this Request are 1) a Statement from the added inventor that the error in inventorship occurred without deceptive intent on his part; 2) a new Declaration signed by the original named inventor and the added inventor; 3) a Statement under 37 C.F.R. 3.73(b) verifying ownership of the instant application; and 4) a statement of consent to the change in inventorship signed by an authorized officer of the Assignee. Accordingly, this Request meets all of the requirements set forth in 37 C.F.R. §1.48(a), parts (1) through (5). Consideration and granting of the Request are respectfully requested.

Dated: June 21, 2005

Respectfully submitted,


Richard J. Steiner
Reg. No. 35,372

Customer Number 007470

(212) 819-8200

Agent's Direct Line:

(212) 819-8783

Enclosures

RECEIVED
CENTRAL FAX CENTER

1103326-0678

JUN 21 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : A. Bayati
Serial No. : 10/053,279 Examiner: Michael Hartley
Filed : January 17, 2002 Group Art Unit: 1616
For : THERAPY FOR FUNCTIONAL DYSPEPSIA

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. §1.48(a)(2)

Sir:

I, Claes Ekman, am an inventor of the claimed subject matter in the above-referenced application. I hereby state that my omission as a named inventor when the application was originally filed occurred without deceptive intent on my part.

I hereby declare that all statements made herein of my own knowledge are true and all statements made on information and belief are believed to be true; and further that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

and such willful false statements may jeopardize the validity of
the application or any patent issued thereon.

Dated: 12 MAY , 2005



Claes Ekman

Docket Number: 100619-1

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

THERAPY,

the specification of which is attached hereto unless the following box is checked:

☒ was filed on 17 Jan. 2002 as United States Application Number 10/053279 or PCT International Application Number _____ and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

Number	Country	Day/Month/Year Filed

☐☐

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application Number)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Number)

(Filing Date)

(Status--patented, pending, abandoned)

(Application Number)

(Filing Date)

(Status--patented, pending, abandoned)


I/we hereby appoint **Practitioners at Customer Number 007470** as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Address all correspondence to **Customer No. 007470**
Telephone No.: 212-819-8200;
Facsimile No.: 212-354-8113

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believe to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (first name, middle initial, last name): Alfred Bayati

First inventor's signature




Date:

17 May 2005Residence: Floda, SwedenCitizenship: SwedishPost Office Address: AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden

☒ Additional inventors are named on the page(s) attached hereto.

Full name of second inventor (first name, middle initial, last name): Claes Ekman

Second inventor's signature  Date: 12 MAY 05

Residence: Lerum, Sweden Citizenship: Swedish

Post Office Address: AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden

PTO/SB/96 (09-04)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(B)Applicant/Patent Owner: Alfred BayatiApplication No./Patent No.: 10/053,279 Filed/Issue Date: January 17, 2002Entitled: THERAPY FOR FUNCTIONAL DYSPEPSIA (amended)(Name of Assignee) AstraZeneca AB a Corporation
(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title and interest; or
2. ☐ an assignee of less than the entire right, title and interest.

The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 012809, Frame 0127, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

(NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Christer WahlströmSignature
Christer WahlströmCHRISTER WAHLSTROMPrinted or Typed Name
Director, Patent OperationsMay 9, 2005Date
011-46-8-553-214-78+46 8 553 214 78

Telephone Number

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22314-50. DO NOT SENT FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

1103326-0678

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : A. Bayati
Serial No. : 10/053,279 Examiner: Michael Hartley
Filed : January 17, 2002 Group Art Unit: 1616
For : THERAPY FOR FUNCTIONAL DYSPEPSIA

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

ASSENT OF ASSIGNEE TO CORRECTION AND/OR ADDITION OF INVENTOR(S)

Sir:

I, Christer Wahlström, am an officer of, and am authorized to act on behalf of, AstraZeneca AB, the Assignee of the entire right, title and interest in the above referenced application. Accompanying this document is a Statement under 37 CFR 3.73(b), also signed by me, attesting to the ownership of this application by AstraZeneca AB. Assignee hereby assents to the correction of inventorship being filed concurrently herewith.

Dated: May 9, 2005



Christer Wahlström